325.73

3.40% -12.34

Praxis Precision Medicines Inc (PRAX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$338.07

Offen:

$349

24-Stunden-Volumen:

249.82K

Relative Volume:

0.61

Marktkapitalisierung:

$9.08B

Einnahmen:

$7.46M

Nettoeinkommen (Verlust:

$-303.27M

KGV:

-24.19

EPS:

-13.4668

Netto-Cashflow:

$-249.12M

1W Leistung:

+2.43%

1M Leistung:

+6.49%

6M Leistung:

+94.14%

1J Leistung:

+757.39%

1-Tages-Spanne:

$317.92

$353.00

1-Wochen-Bereich:

$310.00

$353.00

52-Wochen-Spanne:

$35.21

$356.00

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Firmenname

Praxis Precision Medicines Inc

Sektor

Healthcare (1115)

Branche

Biotechnology (621)

Telefon

617-300-8460

Adresse

99 HIGH STREET, 30TH FLOOR, BOSTON

Mitarbeiter

10,998

Twitter

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRAX Praxis Precision Medicines Inc	325.88	9.42B	7.46M	-303.27M	-249.12M	-13.47
VRTX Vertex Pharmaceuticals Inc	427.18	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	712.38	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	786.32	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.33	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.25	32.51B	5.36B	287.73M	924.18M	2.5229

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-10	Eingeleitet	Raymond James	Strong Buy
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2026-02-02	Eingeleitet	Wells Fargo	Equal Weight
2025-12-15	Bestätigt	Oppenheimer	Outperform
2025-11-19	Eingeleitet	BTIG Research	Buy
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-05-07	Eingeleitet	Chardan Capital Markets	Buy
2025-03-03	Bestätigt	H.C. Wainwright	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-08-05	Eingeleitet	Oppenheimer	Outperform
2024-06-24	Eingeleitet	Needham	Buy
2024-06-18	Eingeleitet	Guggenheim	Buy
2024-05-01	Eingeleitet	Robert W. Baird	Outperform
2023-09-19	Eingeleitet	Truist	Buy
2022-06-06	Herabstufung	Wedbush	Outperform → Neutral
2021-12-16	Eingeleitet	H.C. Wainwright	Buy
2021-08-26	Eingeleitet	BofA Securities	Buy
2021-04-26	Eingeleitet	William Blair	Outperform
2020-11-11	Eingeleitet	Wedbush	Outperform
2020-11-10	Eingeleitet	Cowen	Outperform
2020-11-10	Eingeleitet	Evercore ISI	Outperform
2020-11-10	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten

09:06 AM

Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance - Stock Titan

09:06 AM

08:02 AM

A seizure drug cut monthly seizures 77% as Praxis nears 2 FDA calls - Stock Titan

08:02 AM

08:00 AM

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewswire

08:00 AM

May 06, 2026

Praxis earnings up next as biotech nears commercial transformation - Investing.com

May 06, 2026

LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795 - Moomoo

May 06, 2026

FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares - Stock Titan

May 06, 2026

Price-Driven Insight from (PRAX) for Rule-Based Strategy - Stock Traders Daily

May 06, 2026

May 05, 2026

Praxis gives 21 new employees stock awards tied to hiring - Stock Titan

May 05, 2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 05, 2026

Praxis Precision Medicines Inc expected to post a loss of $3.57 a shareEarnings Preview - TradingView

May 05, 2026

May 04, 2026

Praxis Precision Medicines (PRAX.US) will release its earnings report before the market opens on May 7. - Moomoo

May 04, 2026

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference - The Manila Times

May 04, 2026

Praxis maps out two investor events in May, starting with Q1 results - Stock Titan

May 04, 2026

PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill

May 04, 2026

May 03, 2026

Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN

May 03, 2026

Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge? - Yahoo Finance

May 03, 2026

A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns - Yahoo Finance

May 03, 2026

Apr 30, 2026

Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan

Apr 30, 2026

Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan

Apr 30, 2026

Apr 29, 2026

LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $567 - Moomoo

Apr 29, 2026

Analysts Project Growth for Praxis Precision Medicines Biotech Stock - HarianBasis.co

Apr 29, 2026

Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Insider Monkey

Apr 29, 2026

Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Apr 29, 2026

Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Apr 29, 2026

Praxis Precision Medicines stock drops 2.74% as positive Phase 3 Essential Tremor data shared at AANAM - Traders Union

Apr 29, 2026

Apr 28, 2026

How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates - simplywall.st

Apr 28, 2026

10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey

Apr 28, 2026

Apr 27, 2026

Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co

Apr 27, 2026